Swiss National Bank
TVTX icon

Swiss National Bank’s Travere Therapeutics TVTX Stock Holding History

Swiss National Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.99M Buy
168,100
+1,000
+0.6% +$29.9K ﹤0.01% 1373
2025
Q4 		$6.38M Buy
167,100
+3,500
+2% +$114K ﹤0.01% 1214
2025
Q3 		$3.91M Buy
163,600
+2,500
+2% +$47K ﹤0.01% 1459
2025
Q2 		$2.38M Buy
161,100
+3,000
+2% +$49.7K ﹤0.01% 1696
2025
Q1 		$2.83M Buy
158,100
+6,200
+4% +$126K ﹤0.01% 1573
2024
Q4 		$2.65M Buy
151,900
+17,200
+13% +$304K ﹤0.01% 1698
2024
Q3 		$1.88M Hold
134,700
– – ﹤0.01% 1903
2024
Q2 		$1.11M Sell
134,700
-12,900
-9% -$86.9K ﹤0.01% 2129
2024
Q1 		$1.14M Hold
147,600
– – ﹤0.01% 2153
2023
Q4 		$1.33M Hold
147,600
– – ﹤0.01% 2083
2023
Q3 		$1.32M Buy
147,600
+9,700
+7% +$137K ﹤0.01% 2088
2023
Q2 		$2.12M Sell
137,900
-2,800
-2% -$50.9K ﹤0.01% 1849
2023
Q1 		$3.16M Buy
140,700
+9,400
+7% +$200K ﹤0.01% 1553
2022
Q4 		$2.76M Buy
131,300
+3,300
+3% +$69.9K ﹤0.01% 1682
2022
Q3 		$3.15M Buy
128,000
+1,400
+1% +$36.2K ﹤0.01% 1566
2022
Q2 		$3.07M Sell
126,600
-3,700
-3% -$93.1K ﹤0.01% 1624
2022
Q1 		$3.36M Buy
130,300
+10,100
+8% +$268K ﹤0.01% 1712
2021
Q4 		$3.73M Hold
120,200
– – ﹤0.01% 1659
2021
Q3 		$2.92M Buy
120,200
+5,900
+5% +$108K ﹤0.01% 1802
2021
Q2 		$1.67M Sell
114,300
-4,200
-4% -$82.8K ﹤0.01% 2223
2021
Q1 		$2.96M Buy
118,500
+20,700
+21% +$572K ﹤0.01% 1769
2020
Q4 		$2.67M Buy
97,800
+2,100
+2% +$49K ﹤0.01% 1747
2020
Q3 		$1.77M Buy
95,700
+1,700
+2% +$33K ﹤0.01% 1781
2020
Q2 		$1.92M Buy
94,000
+19,000
+25% +$303K ﹤0.01% 1737
2020
Q1 		$1.09M Buy
75,000
+1,000
+1% +$15K ﹤0.01% 1782
2019
Q4 		$1.05M Buy
74,000
+4,600
+7% +$58.8K ﹤0.01% 2115
2019
Q3 		$804K Hold
69,400
– – ﹤0.01% 2166
2019
Q2 		$1.39M Buy
69,400
+1,700
+3% +$33.6K ﹤0.01% 1930
2019
Q1 		$1.53M Buy
67,700
+4,000
+6% +$88.4K ﹤0.01% 1829
2018
Q4 		$1.44M Hold
63,700
– – ﹤0.01% 1775
2018
Q3 		$1.83M Hold
63,700
– – ﹤0.01% 1771
2018
Q2 		$1.74M Hold
63,700
– – ﹤0.01% 1790
2018
Q1 		$1.42M Buy
63,700
+4,000
+7% +$95.3K ﹤0.01% 1862
2017
Q4 		$1.26M Hold
59,700
– – ﹤0.01% 1949
2017
Q3 		$1.49M Hold
59,700
– – ﹤0.01% 1818
2017
Q2 		$1.16M Buy
59,700
+6,300
+12% +$114K ﹤0.01% 1956
2017
Q1 		$986K Hold
53,400
– – ﹤0.01% 2041
2016
Q4 		$1.01M Hold
53,400
– – ﹤0.01% 2028
2016
Q3 		$1.2M Sell
53,400
-2,800
-5% -$53.3K ﹤0.01% 1856
2016
Q2 		$1M Buy
56,200
+6,300
+13% +$102K ﹤0.01% 1964
2016
Q1 		$656K Buy
49,900
+11,700
+31% +$177K ﹤0.01% 2158
2015
Q4 		$737K Hold
38,200
– – ﹤0.01% 2037
2015
Q3 		$774K Buy
38,200
+6,500
+21% +$193K ﹤0.01% 1932
2015
Q2 		$1.05M Buy
+31,700
New +$868K ﹤0.01% 1766

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swiss National Bank's TVTX Position: Q1 2026 in Review

Swiss National Bank increased its Travere Therapeutics (TVTX) stake by 0.6% in Q1 2026, buying an estimated $29.9K and bringing the position to 168,100 shares worth $4.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1373.

Swiss National Bank first reported a position in TVTX in Q2 2015 and has held it in 44 quarters since. The position peaked at $6.38M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Swiss National Bank held 168,100 shares of Travere Therapeutics worth $4.99M as of Q1 2026.
  • Swiss National Bank bought 1,000 Travere Therapeutics shares in Q1 2026, an estimated $29.9K.
  • Travere Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1373 holding.
  • Swiss National Bank first reported a position in Travere Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Swiss National Bank's Travere Therapeutics position peaked at $6.38M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.